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Abstract
Multidrug resistant (MDR) tuberculosis is caused by Mycobacterium tuberculosis resistant to isoniazid and rifampicin, the two
most effective drugs used in tuberculosis therapy. Here, we investigated the mechanism by which resistance towards
isoniazid develops and how overexpression of efflux pumps favors accumulation of mutations in isoniazid targets, thus
establishing a MDR phenotype. The study was based on the in vitro induction of an isoniazid resistant phenotype by
prolonged serial exposure of M. tuberculosis strains to the critical concentration of isoniazid employed for determination of
drug susceptibility testing in clinical isolates. Results show that susceptible and rifampicin monoresistant strains exposed to
this concentration become resistant to isoniazid after three weeks; and that resistance observed for the majority of these
strains could be reduced by means of efflux pumps inhibitors. RT-qPCR assessment of efflux pump genes expression
showed overexpression of all tested genes. Enhanced real-time efflux of ethidium bromide, a common efflux pump
substrate, was also observed, showing a clear relation between overexpression of the genes and increased efflux pump
function. Further exposure to isoniazid resulted in the selection and stabilization of spontaneous mutations and deletions in
the katG gene along with sustained increased efflux activity. Together, results demonstrate the relevance of efflux pumps as
one of the factors of isoniazid resistance in M. tuberculosis. These results support the hypothesis that activity of efflux pumps
allows the maintenance of an isoniazid resistant population in a sub-optimally treated patient from which isoniazid
genetically resistant mutants emerge. Therefore, the use of inhibitors of efflux should be considered in the development of
new therapeutic strategies for preventing the emergence of MDR-TB during treatment.
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Introduction
Tuberculosis (TB) remains a serious public health threat around
the world, and according to the World Health Organization,
nearly two billion people are infected with Mycobacterium tuberculosis,
with about 8.8 million of new TB cases and 1.3 million deaths in
2010 [1]. Moreover, multidrug resistant tuberculosis (MDR-TB),
caused by M. tuberculosis simultaneously resistant to isoniazid and
rifampicin, the two most effective anti-bacillary drugs used in TB
therapy, represents a challenge to the control of the disease since
650,000 of the TB cases in 2010 are estimated to be MDR-TB
cases [1].
Chromosomal gene mutation has been considered the single
cause for antibiotic resistance in M. tuberculosis, with multidrug
resistance arising as a consequence of sequential accumulation of
spontaneous mutations in target genes [2]. Resistance to
rifampicin is almost always due to point mutations in the rpoB
gene encoding the b subunit of the RNA polymerase [3].
Furthermore, monoresistance to rifampicin is rare and almost all
M. tuberculosis strains resistant to rifampicin are also resistant to
isoniazid [2,4,5]. Isoniazid is a prodrug that requires activation by
the catalase-peroxidase enzyme (KatG) [6] and its molecular
target is InhA, a NADH-dependent enoyl acyl carrier protein
reductase involved in the synthesis of mycolic acids [7]. The main
mechanism of resistance to isoniazid is the occurrence of
mutations in its activator, KatG [6,8], whereas mutations in the
inhA gene represent the second most common mechanism.
Together, mutations in these two genes are responsible for
approximately 75% of the cases of M. tuberculosis resistance to
isoniazid in the clinical setting [9]. Resistance to isoniazid has also
been associated with mutations in several other genes (e.g. ndh, kasA
and oxyR–ahpC intergenic region) [10], but its direct association
with resistance is still unclear.
Isoniazid is highly effective against M. tuberculosis (bactericidal at
low concentrations), the reason why it remains a key component in
multiple drug treatment regimens. However, resistant isolates are
rapidly generated during monotherapy or inappropriate treat-
ment, and many clinical isolates with no identified mutation have
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resistant phenotypes also receive significant contributions from
membrane transport proteins that prevent the compound from
reaching the cellular target [12,13]. The analysis of genome
sequences has shown that mycobacteria have multiple putative
efflux pumps [14] and to date, several pumps have been identified
in various species of mycobacteria in association with low level
resistance to various compounds, including isoniazid [15–20].
In general, increased activity of efflux systems is responsible for
conferring low-level resistance to antibiotics, contrasting with the
high-level resistance caused by mutations in genes encoding for the
primary targets of these antibiotics [21]. Increased activity of efflux
systems results in the reduction of intracellular levels of the
antibiotic, which may enable the survival of a bacterial
subpopulation under constant stress promoted by a sub-lethal
level of antibiotic. During this period, mutants with alterations in
the genes that favour resistance can be selected, therefore insuring
the establishment of an antibiotic resistant population that is
clinically significant [22–24]. It is this sub-population of bacteria
that may then accumulate mutations with prolonged exposure to a
constant concentration of antibiotic [25,26].
Here, we investigated the mechanisms underlying the develop-
ment of multidrug resistance in M. tuberculosis via the constant
exposure of several isoniazid susceptible M. tuberculosis strains to
the critical concentration of isoniazid, 0.1 mg/ml; followed by the
evaluation of the effect of efflux inhibitors on the isoniazid
minimum inhibitory concentration for the original and isoniazid
exposed resistant strains. Analysis of gene expression of six efflux
pumps related to isoniazid resistance in M. tuberculosis [12,15,19]
and its correlation with the cell’s ability to efflux ethidium bromide
(a common efflux substrate), provides strong evidence that when
challenged with isoniazid, M. tuberculosis reacts by a prompt efflux-
mediated response. We further demonstrate that this isoniazid
induced resistance can be reverted by efflux inhibitors, supporting
their role as adjuvants in anti-tuberculosis therapy and prevention
of MDR-TB emergence.
Results
Exposure to isoniazid
Two M. tuberculosis strains susceptible to the first-line antibiotics
(including the H37Rv reference strain) and two clinical strains
monoresistant to rifampicin were constantly exposed to the critical
concentration of isoniazid, 0.1 mg/ml, during an extended period
of time – see Figure 1. Two independent exposure processes were
carried out for each strain (exposure process A and B in Figure 1)
to assess the stochastic behaviour of the biological events involved.
The effect of 0.1 mg/ml isoniazid exposure on the minimum
inhibitory concentration of isoniazid (INH MIC) is summarised in
Table 1. Briefly, INH MIC increases from an initial value of 0.05–
0.1 mg/ml to as high as 256 mg/ml (Table 1). Exposure to
isoniazid had no effect on the MIC of rifampicin against all strains
(data not shown). Additionally, susceptibility testing for the five 1
st
line antibiotics (streptomycin, isoniazid, rifampicin, ethambutol
and pyrazinamide) applied to all strains at the beginning of the
experiments and after the last passage in isoniazid indicated that
development of resistance was restricted to isoniazid only (data not
shown). We also observed that the time required for growth
detection decreased with the number of passages (Table 1).
Typing by MIRU-VNTR analysis
To confirm the isogenic nature of the exposed and initial
parental strains, all strains were subjected to molecular typing by
MIRU-VNTR analysis, which confirmed the identity of each
culture during the antibiotic exposure processes (Tables 2 and 3).
Detection of mutations associated with isoniazid
resistance
Cultures corresponding to selected passages of isoniazid
exposure were preliminarily monitored for mutations in katG and
mabA-inhA operon by the Genotype MTBDRplus system. These
strains were later analyzed by DNA sequencing of specific
fragments of these same genes – see Tables 2 and 3.
For strain H37Rv, two different results were obtained for the
two independent isoniazid exposure processes. In one of the
duplicates, total deletion of katG gene was observed at passage #3
(H37RvINH(a)3, GenBank accession number JQ406585). The
precise extent and location of this deletion was defined by
sequencing and chromosomal primer walking to be located
between positions 59-2150314 and 59-2159943 of the M. tuberculosis
H37Rv genome [14]. This deletion, 8084 bp in length, resulted in
the complete loss of genes Rv1903, Rv1904, aao, Rv1906c, Rv1907c,
katG, furA, Rv1910c, lppc and disruption of fadB5 (Figure 2).
Conversely, no alterations were detected on katG or any of the
other gene targets tested during strain H37Rv second isoniazid
exposure process (cf. Tables 2 and 3). Interestingly, both isoniazid-
exposed cultures evidenced the same levels of resistance at
equivalent passages of the exposure process (Table 1). For the
three clinical strains subjected to the same isoniazid exposure
process, no alterations were detected, except for the appearance of
a STOP codon in position 1314 of the katG gene (codon 438) for
strain 359/03 This alteration occurred at passage #2 (359/
03INH(a)2, accession number JQ316462) of the first exposure
process (Table 2), whereas no alteration was detected in the second
exposure process of this same strain (Table 3). Again, no
differences were observed between the isoniazid resistance levels
of the two isoniazid-exposed 359/03 cultures (Table 1).
Effect of EIs on the susceptibility to isoniazid
To test for the involvement of efflux on the increased resistance
to isoniazid noticed through the exposure process, we determined
the INH MIC in the first passage where this increased resistance
was first noticed and in last passage (#26) of the exposure process,
in the absence and presence of compounds known to act as efflux
inhibitors (EIs). The compounds selected were thioridazine,
chlorpromazine and verapamil, for which inhibitory activity
against mycobacterial efflux pumps was already demonstrated
[16,27,28]. The effects of these EIs on the INH MICs are
summarized in Table 4. The INH MIC was reduced by
thioridazine, chlorpromazine and verapamil to levels equal or
below the critical concentration used for the standard susceptibility
testing of this antibiotic in the majority of cases. We then assayed
the efflux activity of these cultures by a semi-automated
fluorometric method [27,29], which uses the broad-range efflux
substrate EtBr, in the presence and absence of an EI.
Real-time detection of efflux activity
The assays were performed for all isoniazid non-exposed strains
(#0) and at passages #1 and #26 of the two exposure processes (A
and B).
The EtBr accumulation assays, used to determine the highest
concentration of EtBr that cells can handle without detectable
accumulation (see Material and Materials), showed that the
clinical strains are able to handle higher EtBr concentrations than
H37Rv (0.25–0.5 and 0.125 mg/ml of EtBr, respectively – see
values at bold type in legends of Figure 3A). This means that the
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equilibrium is higher for the clinical strains than for H37Rv, i.e.
that the former have higher efflux capacity than that of the
reference strain [29]. With exposure to isoniazid, this efflux
capacity increase, as shown by the flatness of the accumulation
curves observed for all cultures at the first step of isoniazid
exposure (Fig. 3B). With continuation of exposure to isoniazid, this
efflux activity decreases, as shown by the lower EtBr concentra-
tions needed to reach observable accumulation for cultures at
passage #26 (cf. Fig. 3C with 3B), however not to the original
levels shown by the non-exposed cultures (cf. Fig. 3C with 3A).
Interestingly, this decrease of efflux activity with the prolonged
exposure to isoniazid is observable for the clinical strains but not
for H37Rv. For the sake of space, only the results for exposure
process A are shown in Figure 3, but the same behavior was
obtained for the exposure process B, for all the strains.
Figure 1. Schematic representation of exposure of strain H37Rv to 0.1 mg/ml INH using the BACTEC
TM MGIT
TM 960 and
characterization assays performed at selected points. For each strain, exposure to INH was done in duplicate, in two independent assays -
processes A and B. INH(a): exposure process A; INH(b): exposure process B; INH: isoniazid; EI: efflux inhibitor. Vertical arrows represent transfer to new
MGIT tubes containing 0.1 mg/ml INH. Seq: nucleotide sequence determination for specific fragments of the genes involved in the resistance to INH;
AST: susceptibility testing to all first line antibiotics. MICINH: minimum inhibitory concentration determination of isoniazid. Note: This same procedure,
here depicted as an example, was carried out for isoniazid exposure of each strain involved in this study.
doi:10.1371/journal.pone.0034538.g001
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tions for which influx-efflux are at equilibrium, but now in the
presence of verapamil (efflux inhibitor) at sub-inhibitory concen-
trations (see dotted curves in Figure 3). Results clearly show that
inhibition of efflux occurs, leading to an increased EtBr
accumulation within cells. Again, this effect is more pronounced
at the first step of isoniazid exposure (passage #1), except for
H37Rv, which reinforces the hypothesis that this is the step in
which the increase of efflux activity is more significant. Similar
results were obtained for thioridazine and chlorpromazine,
however with lower inhibitory effect (data not shown).
Table 1. The effect of serial passages in a constant concentration of isoniazid (0.1 mg/ml) on the INH MIC and the number of days
required for detection of growth.
INH MIC (mg/ml) (days required for detection of growth)
#0 #1 #2 #3 #5 #13 #26
Fully susceptible strains
H37Rv INH (a) 0.05 (-) 128 (19) 128 (5) 128 (4) 128 (4) 128 (4) 128 (4)
H37Rv INH (b) 0.05 (-) 128 (14) 128 (8) 128 (5) 128 (3) 128 (3) 128 (3)
401/06 INH (a) 0.1 (-) 256 (20) 256 (6) 256 (4) 256 (4) 256 (4) 256 (3)
401/06 INH (b) 0.1 (-) 64 (32) 256 (14) 256 (18) 256 (7) 256 (4) 256 (3)
Rifampicin monoresistant strains
267/05 INH (a) 0.1 (-) 128 (15) 128 (7) 128 (4) 128 (6) 128 (3) 128 (3)
267/05 INH (b) 0.1 (-) 128 (17) 128 (5) 128 (4) 128 (7) 128 (4) 128 (3)
359/03 INH (a) 0.05 (-) 256 (18) 256 (13) 256 (6) 256 (4) 256 (4) 256 (3)
359/03 INH (b) 0.05 (-) 128 (17) 256 (16) 256 (3) 256 (3) 256 (8) 256 (3)
Legend: INH: isoniazid; RIF: rifampicin; INH (a)/(b): adaptation processes to isoniazid A and B, respectively.
doi:10.1371/journal.pone.0034538.t001
Table 2. Genotypic characterization of the strains and derived cultures exposed to isoniazid (adaptation process A).
Genotype MTBDRplus DNA Sequencing
Strain/Passage rpoB mabA-inhA katG mabA-inhA katG MIRU-VNTR profile
H37Rv Wt wt wt wt wt H37Rv
H37Rv INH (a)1 Wt wt wt wt wt H37Rv
H37Rv INH (a)2 Wt wt wt wt wt
H37Rv INH (a)3 Wt wt D katG wt D katG
H37Rv INH (a)5 Wt wt D katG wt D katG H37Rv
H37Rv INH (a)13 Wt wt D katG wt D katG
H37Rv INH (a)26 Wt wt D katG wt D katG H37Rv
401/06 Wt wt wt wt wt A
401/06 INH (a)5 Wt wt wt wt wt A
401/06 INH (a)13 Wt wt wt wt wt
401/06 INH (a)26 Wt wt wt wt wt A
267/05 S531L wt wt wt wt B
267/05 INH (a)5 S531L wt wt wt wt B
267/05 INH (a)13 S531L wt wt wt wt
267/05 INH (a)26 S531L wt wt wt wt B
359/03 S531L wt wt wt wt C
359/03 INH (a)1 S531L wt wt wt wt C
359/03 INH (a)2 S531L wt wt wt TGG438RSTOP
359/03 INH (a)5 S531L wt wt wt TGG438RSTOP C
359/03 INH (a)13 S531L wt wt wt TGG438RSTOP
359/03 INH (a)26 S531L wt wt wt TGG438RSTOP C
Legend: INH: isoniazid; RIF: rifampicin; wt: wild type; D: deletion of katG gene; S: serine; L: leucine. MIRU-VNTR profile A: 2,4,2,2,3,4,2,3,2,3,2,4,2,2,6,1,6,3,1,3,1,7,2,2;
profile B: 2,4,4,2,3,4,3,3,2,4,2,4,2,2,6,1,5,3,1,3,1,5,2,2; profile C: 2,1,4,2,1,3,2,3,2,2,2,5,1,2,6,1,6,3,3,3,2,4,2,2.
doi:10.1371/journal.pone.0034538.t002
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the main M. tuberculosis efflux pumps for cultures at the different
isoniazid exposure steps.
Expression analysis of genes coding for efflux pumps in
response to isoniazid
The analysis of the relative expression of efflux pump genes
previously identified as transporters of isoniazid was performed for
all strains at passages #1 and #26. As detailed in Material and
Methods, the expression levels of these genes were determined in
the presence of isoniazid and compared to those obtained for the
non-exposed culture (#0) [30].
Table 5 shows that the four strains reacted to the presence of
isoniazid by overexpressing the majority of the efflux pump genes
tested in a way that is not consistent among the two isoniazid
exposures processes to which each strain was submitted.
Additionally, and perhaps the most striking observation resulting
from expression data, was the absence of a clearly defined pattern
of gene expression in response to isoniazid exposure. Nevertheless,
a general and strong increase in the expression was observed for
the majority of the genes tested, mmpL7, p55, efpA, mmr, Rv1258c
and Rv2459.
Discussion
In this work, we addressed three questions related to the
molecular mechanisms involved in M. tuberculosis resistance to
isoniazid: i. What are the effects of continuous exposure of M.
tuberculosis strains to the critical concentration of isoniazid? ii.
What are the biological events involved, in particular, which is the
role played by efflux pumps in the emergence of resistance? and,
iii. Does the final outcome vary when independent exposures are
performed for the same strain?
For this purpose, we studied a panel of four M. tuberculosis
strains, two fully susceptible and two monoresistant to rifampicin,
through their independent exposure to a constant concentration of
0.1 mg/ml of isoniazid. During this process, strains became
phenotypically resistant with an increase in their INH MIC
exceeding 64 mg/ml, which is considered high-level resistance.
The susceptibility towards the other 1
st line anti-tuberculosis drugs
was not affected by this process, indicating the development of an
isoniazid specific resistance mechanism.
In terms of the biological events occurring during exposure to
isoniazid (question ii), we observed that for two strains, alterations
occurred at the katG gene, corresponding to a full deletion in the
case of H37Rv and the introduction of a stop codon for strain
359/03. Both alteration occurred early in the exposure process
Table 3. Genotypic characterization of the strains and derived cultures adapted to isoniazid (adaptation process B).
Genotype MTBDRplus DNA Sequencing
Strain/Passage rpoB mabA-inhA katG mabA-inhA katG MIRU-VNTR profile
H37Rv INH (b)5 Wt wt wt wt wt H37Rv
H37Rv INH (b)13 Wt wt wt wt wt
H37Rv INH (b)26 Wt wt wt wt wt H37Rv
401/06 INH (b)5 Wt wt wt wt wt A
401/06 INH (b)13 Wt wt wt wt wt
401/06 INH (b)26 Wt wt wt wt wt A
267/05 INH (b)5 S 5 3 1 L w t w t w tw tB
267/05 INH (b)13 S531L wt wt wt wt
267/05 INH (b)26 S 5 3 1 L w t w t w tw tB
359/03 INH (b)5 S 5 3 1 L w t w t w tw tC
359/03 INH (b)13 S531L wt wt wt wt
359/03 INH (b)26 S 5 3 1 L w t w t w tw tC
Legend: INH: isoniazid; RIF: rifampicin; wt: wild type; S: serine; L: leucine. MIRU-VNTR profile A: 2,4,2,2,3,4,2,3,2,3,2,4,2,2,6,1,6,3,1,3,1,7,2,2; profile B:
2,4,4,2,3,4,3,3,2,4,2,4,2,2,6,1,5,3,1,3,1,5,2,2; profile C: 2,1,4,2,1,3,2,3,2,2,2,5,1,2,6,1,6,3,3,3,2,4,2,2.
doi:10.1371/journal.pone.0034538.t003
Figure 2. Map of the region deleted in the M. tuberculosis H37Rv reference strain as a result of the exposure to isoniazid. The region
analyzed spans from positions 59-2150314 to 59-2159943 of the M. tuberculosis H37Rv genome sequence [14], adapted from Tuberculist, 2010, http://
tuberculist.epfl.ch/. The area delimited corresponds to the fragment deleted in strain H37RvINH(a)3.
doi:10.1371/journal.pone.0034538.g002
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alterations in katG correlated with the loss of catalase activity (data
not shown). The mutation found in clinical isolate 359/03 is rarely
described in literature; however it fits into the known strategy of
KatG functional weakening by introduction of mutations during
isoniazid exposure [10,31]. Others have also reported the in vitro
deletion of total or part of the katG gene in strains exposed to
isoniazid [31,32], and total/partial deletion of the katG gene of
isoniazid-resistant clinical isolates has also been previously
reported [8,33]. Interestingly, no genetic changes were detected
in the second isoniazid-exposure procedure, run in parallel for
these same strains, indicating that evolution of the same strain in
the same conditions can bring about, in a non-deterministic
course, cells that significantly differ both phenotypically and
genetically.
Our results clearly show that, in addition to the occurrence of
spontaneous mutations, efflux systems play a role in the
development of isoniazid resistance. This occurs quite early during
exposure to isoniazid and allows cells to survive in the presence of
this antibiotic until a mutation conferring high level and stable
resistance emerges. Recently, Srivastava et al., suggested a model
for the development of drug resistance in the M. tuberculosis
reference strain H37Rv, enabling the rapid emergence of high
level resistance to both ethambutol and isoniazid [34]. In this
model, it is proposed that induction of an efflux pump which
transports two or more drugs is the first step to the emergence of
resistance. Our results provide the experimental data that confirm
the model proposed by these authors and demonstrate that this
mechanism is extendable to clinical isolates.
Moreover, our work provides, for the first time, data captured
on a real-time basis for increased efflux activity as the first-line
response of M. tuberculosis to the critical concentration of isoniazid.
This efflux-mediated response was detected for both susceptible
and rifampicin monoresistant, reference or clinical strains and
provide the cells with a rapid, non specific response to a highly
noxious agent. As the isoniazid exposure process continues, two
different patterns were observed: the susceptible reference strain
H37Rv increased its efflux activity, even after deletion of the entire
katG gene, whereas the clinical strains showed a decreased efflux
activity in the last passage of isoniazid exposure. During the entire
process, the clinical strains showed a capacity to handle higher
EtBr concentrations than H37Rv, an additional evidence of their
higher efflux capacity. Overall, the clinical strains appear to be
more prompt to respond, via an efflux-mediated pathway, to
noxious agents, such as EtBr or isoniazid, whereas H37Rv shows a
less prompt, but more stable/prolonged use of efflux as a
detoxifying response to these drugs. These results suggest that
clinical M. tuberculosis strains are primed to efflux noxious
compounds, as already observed in other bacteria [35]. The
presence of such efflux system(s) and their role in resistance to
these drugs was additionally confirmed by the use of efflux
inhibitors in both real-time efflux assays and MIC determinations.
While in the first assays, these compounds were able to reduce
efflux of EtBr, their use in INH MIC determination showed the
involvement of efflux on the high level resistance to this antibiotic.
For some strains, the reduction on INH MIC by the EIs tested
reached levels identical to their susceptible parental counterparts.
This clearly shows that in these cases, high level isoniazid
resistance is mainly efflux-driven. From the several inhibitors
tested, chlorpromazine and verapamil were the two most effective
for inhibiting isoniazid efflux in M. tuberculosis, as previously
demonstrated for M. tuberculosis complex [36].
It is worth noticing that EIs show a more significant effect on the
MICs for cultures at first passage compared to their effect on the
MICs of the last passage (#26). For strain 401/06, submitted to
exposure process A, despite the fact that no evident genetic
alteration was detected, the high INH MIC obtained after
isoniazid exposure could not be reduced by any of the EIs tested
(Table 4). This result suggests that, for this culture, the isoniazid
high level resistance detectable at first passage is already mutation-
driven. Interestingly strain 267/05, without detectable mutations is
the one with the highest level of expression of genes for efflux
further supporting that overexpression of efflux-pumps can sustain
isoniazid resistance to levels as high as those achieved by the
canonical mutations.
To identify the efflux system(s) involved in this first-line response
to isoniazid, we selected a set of genes coding for efflux pumps
reported to be involved in the transport of noxious substances,
Table 4. MIC determination and susceptibility testing for the strains exposed to isoniazid in the presence and absence of efflux
inhibitors.
INH MIC (mg/ml) (Susceptibility testing for INH)
#0 #1 #26
Strain +TZ +CPZ +VP no EI +TZ +CPZ +VP no EI +TZ +CPZ +VP
H37Rv INH (a) 0.05 (S) 0.05 (S) 0.05 (S) 128 (R) 128 (R) 0.05 (S) 0.06 (S) 128 (R) 128 (R) 128 (R) 128 (R)
H37Rv INH (b) 0.05 (S) 0.05 (S) 0.05 (S) 128 (R) 128 (R) 0.1 (S) 0.1 (S) 128 (R) 128 (R) 0.1 (S) 0.1 (S)
401/06 INH (a) 0.1 (S) 0.1 (S) 0.1 (S) 256 (R) 256 (R) 128 (R) 256 (R) 256 (R) 256 (R) 128 (R) 256 (R)
401/06 INH (b) 0.1 (S) 0.1 (S) 0.1 (S) 64 (R) 0.1(S) 0.1 (S) 0.1 (S) 256 (R) 256 (R) 64 (R) 256 (R)
267/05 INH (a) 0.1 (S) 0.1 (S) 0.1 (S) 128 (R) 0.1 (S) 0.1 (S) 128 (R) 128 (R) 0.1 (S) 0.1 (S) 128 (R)
267/05 INH (b) 0.1 (S) 0.1 (S) 0.1 (S) 128 (R) 0.1 (S) 0.1 (S) 128 (R) 128 (R) 0.1 (S) 0.1 (S) 128 (R)
359/03 INH (a) 0.05 (S) 0.05 (S) 0.05 (S) 256 (R) 128 (R) 0.1 (S) 0.03 (S) 256 (R) 128 (R) 0.1 (S) 0.03 (S)
359/03 INH (b) 0.05 (S) 0.05 (S) 0.05 (S) 128 (R) 0.1 (S) 0.1 (S) 0.1 (S) 256 (R) 128 (R) 0.1 (S) 0.1 (S)
Legend: INH: isoniazid; INH (a): exposure process A; INH (b): exposure process B. S: susceptible; R: resistant. Values in bold correspond to full reversion of the INH
resistance phenotype. EIs were used at K of their MIC. MICs for the EIs (passage 1): thioridazine (TZ): H37Rv and 359/03: 15 mg/ml, 401/06 and 267/05: 30 mg/ml;
chlorpromazine (CPZ): 30 mg/ml for all strains; verapamil (VP): 256 mg/ml for all strains. MICs for the EIs (passage 26): TZ: H37Rv and 359/03: 15 mg/ml, 401/06(a)26:
15 mg/ml; 401/06(b)26: 30 mg/ml; 267/05: 30 mg/ml; CPZ: MIC of 30 mg/ml for all strains except H37Rv INH(a)26: 15 mg/ml; VP: 256 mg/ml for all strains except H37Rv
INH(a)26 and 401/06: 128 mg/ml.
doi:10.1371/journal.pone.0034538.t004
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PLoS ONE | www.plosone.org 6 April 2012 | Volume 7 | Issue 4 | e34538Figure 3. Accumulation of EtBr by the M. tuberculosis strains tested. The figure shows the accumulation of EtBr by the strains from adaptation
process A as an example. The values at bold type correspond to the higher concentration of EtBr that cells can handle without detectable
accumulation. The dotted line corresponds to the assay run using the EtBr concentrations for which influx-efflux are at equilibrium, in the presence of
the EI verapamil, at sub-inhibitory concentrations. Panel (A): Parental strains (passage #0); Panel (B) strains after first passage with INH and Panel (C);
strains after 26 passages with INH. INH: isoniazid.
doi:10.1371/journal.pone.0034538.g003
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highly increased expression of these genes following isoniazid
exposure, further evidences that an efflux-mediated response
provides an early stress response that creates opportunity for other
resistance mechanisms to arise.
Although we detected a general and marked increase of efflux
pumps genes, most of which being significantly overexpressed, we
also noted the absence of a clearly defined pattern of specific gene
expression in response to isoniazid exposure. Efflux pumps seem to
be promiscuous in their activity as we cannot associate extrusion of
isoniazid to a specific gene. Similar results were obtained by others
regarding the extrusion of rifampicin [38]. As described in
Materials and Methods, the RT-qPCR data were analyzed
considering a cut-off value of fourfold as corresponding to
significant overexpression [39]. This can be considered a stringent
cut-off and somehow limit our analysis [40], since the levels of
gene expression obtained, in comparison to the non-exposed
condition, lied in the majority of the cases, above two/three fold.
Nevertheless, even considering the more stringent value of four, a
clear and general ability to trigger efflux pump genes overexpres-
sion in response to isoniazid presence was observed along the
exposure processes, for all strains. The genes for which a more
consistent isoniazid-mediated response was observed, were the
genes involved in the transport and synthesis of mycolic acids,
mmpL7 and efpA respectively [41,42], and p55, considered to be
involved in isoniazid transport [17,20,38,43,44]. Again, our study
complements other earlier findings [15,34,36], who suggested the
involvement of these genes in the resistance to isoniazid, by
providing experimental data showing that susceptible reference
strain and clinical strains use these pumps as an immediate
response to the presence of isoniazid concentrations that are
considered to be inhibitory.
Finally, concerning the third question raised in this work - does
the final outcome vary when independent exposures are
performed for the same strain, we have found that each strain
may differ at the final outcome of the process of its exposure to the
isoniazid critical concentration, in terms of the resistance
mechanism it may adopt (mutations in different target genes,
etc), although no differences were observed at the resistance level,
which was always well above 64 mg/ml of isoniazid. Nevertheless,
they all respond in a similar way at the first steps of this process
and that is through isoniazid efflux, which may constitute an early
stress response of bacteria against environmental noxious agents
such as appears to be the case for isoniazid. After this first, efflux-
mediated response, evolution may take different non-deterministic
paths conducting to high level resistance. Collectively, these
observations support the experimental strategy followed in this
work that highlighted alternative pathways by which the same M.
tuberculosis strain responds to 0.1 mg/ml isoniazid, all resulting in
the same high resistance level.
In conclusion, constant exposure of M. tuberculosis to the
commonly used critical concentration of isoniazid causes suscep-
tible strains to become highly resistant to this key anti-tuberculosis
drug. The same procedure applied to strains initially mono-
resistant to rifampin results in the development of multidrug
resistance as defined by the WHO, i.e, resistance to isoniazid and
rifampicin. To our knowledge, this is the first presentation of an in
vitro process that mimics the development of multidrug resistant M.
Table 5. Average quantification of the relative expression level, by RT-qPCR, of the genes that code for efflux pumps in M.
tuberculosis in the two independent isoniazid exposure processes.
Relative expression level ± SD
mmpl7 Rv1258c p55 efpA mmr Rv2459
Fully susceptible strains
H37Rv INH(a)1 8.00±2.38 16.00±1.16 13.00±2.23 9.85±1.41 16.65±2.44 25.99±2.56
H37Rv INH(a)26 0.4460.12 1.9960.66 0.8260.15 0.3460.28 0.4460.16 0.5060.02
H37Rv INH(b)1 10.56±3.48 15.26±0.46 6.96±1.36 8.00±2.98 9.95±2.03 22.63±1.56
H37Rv INH(b)26 4.57±0.25 2.5360.03 2.7060.43 4.41±0.21 1.5460.29 2.3160.13
401/06 INH(a)1 34.30±1.24 22.63±0.47 18.38±1.94 16.00±1.32 24.25±2.34 9.19±0.11
401/06 INH(a)26 17.15±0.23 14.93±2.30 9.85±0.99 6.96±1.57 9.19±1.76 27.86±1.3
401/06 INH(b)1 1.5360.29 1.7760.75 3.47±1.16 6.50±1.30 1.4760.07 0.2060.05
401/06 INH(b)26 4.16±0.66 7.80±4.96 11.31±1.11 8.57±2.66 2.2960.77 2.6460.39
Rifampicin monoresistant strains
267/05 INH(a)1 6.06±0.53 4.29±0.24 5.28±0.48 9.85±0.17 3.7360.13 6.50±1.03
267/05 INH(a)26 115.56±59.44 53.85±2.64 110.80±66.17 341.05±66.43 59.06±53.66 32.00±1.98
267/05 INH(b)1 5.01±1.10 2.0060.21 3.1060.43 3.90±0.28 2.6260.54 1.6960.36
267/05 INH(b)26 17.15±1.24 3.0460.29 12.13±0.67 22.63±3.09 3.89±0.57 0.6460.09
359/03 INH(a)1 4.00±0.03 1.6260.54 2.0861.06 1.8760.00 2.0360.86 0.7660.09
359/03 INH(a)26 13.96±1.36 9.01±2.17 8.53±2.86 10.66±2.07 11.46±4.9 32.00±2.01
359/03 INH(b)1 9.85±2.35 5.66±1.24 4.00±0.06 5.11±2.62 6.06±0.54 0.2560.03
359/03 INH(b)26 25.99±1.33 29.86±3.29 29.86±2.56 2.3060.83 10.56±1.36 2.3060.12
Legend: (a)1: exposition process A, first passage; (b)1: exposition process B, first passage; (a)26: exposition process A, passage twenty six; (b)26: exposition process B,
passage twenty six. The relative expression of the efflux pump genes was assessed by comparison of the relative quantity of the respective mRNA in the presence of
isoniazid to the non-exposed strain. Each culture was assayed in triplicate using total RNA obtained from three independent cultures. A level of relative expression equal
to 1 indicates that the expression level was identical to the strain that was being compared. Genes showing expression levels equal or above four, when compared to
the non-exposed strain, were considered to be overexpressed and are shown in bold.
doi:10.1371/journal.pone.0034538.t005
Efflux Mediated INH Resistance in M. tuberculosis
PLoS ONE | www.plosone.org 8 April 2012 | Volume 7 | Issue 4 | e34538tuberculosis strains, which correlates with the anticipated develop-
ment of MDR-TB in a patient treated for prolonged periods with a
constant dose of isoniazid, as needed for effective therapy.
Therefore, the results obtained in this work emphasize the need
for revising isoniazid critical concentration and reinforce the
importance of multiple drug therapy in all anti-tuberculosis
regimens [45,46]. Furthermore, efflux inhibitors like the ones
tested in this work represent relevant alternatives in the search for
new effective compounds and new therapeutic strategies for
preventing the emergence of and possibly in the treatment of
MDR-TB.
Materials and Methods
M. tuberculosis strains
The strains studied included two M. tuberculosis strains
susceptible to the first-line antibiotics, the reference strain
H37Rv ATCC27294
T and a clinical isolate 401/06, plus; two
clinical isolates 359/03 and 267/05, both monoresistant to
rifampicin, harboring the most common rpoB mutation in clinical
isolates, S531L, all from the culture collection of Grupo de
Micobacte ´rias, Unidade de Microbiologia Me ´dica, Instituto de
Higiene e Medicina Tropical (IHMT, UNL).
Cultures, susceptibility testing, minimum inhibitory concentra-
tion (MIC) determination and antibiotic exposure process was
conducted using the BACTEC
TM MGIT
TM 960 system (BAC-
TEC 960) and the Epicenter V5.53A software equipped with the
TB eXIST module (Becton Dickinson Diagnostic Systems, Sparks,
MD, USA).
Antimicrobial agents
The lyophilized drugs (BACTEC
TM MGIT
TM 960 SIRE and
PZA kits; SIRE: streptomycin, isoniazid, rifampicin and etham-
butol; PZA: pyrazinamide) used in the standard susceptibility
testing and in the exposure process to isoniazid and rifampicin
were purchased from Becton Dickinson and the stock solutions
prepared as per the manufacturer’s instructions. Isoniazid for MIC
determination and efflux inhibitors verapamil, thioridazine and
chlorpromazine, as well as the efflux substrate ethidium bromide
(EtBr), were purchased from Sigma-Aldrich (St. Louis, MO, USA).
All drugs were prepared in sterile deionized water.
Exposure process to the critical concentration of
isoniazid
Each strain was exposed to isoniazid (0.1 mg/ml) in duplicate
(Figure 1 – Schematic example for isoniazid exposure of strain
H37Rv ATCC27294
T). This concentration is defined as the lowest
concentration necessary to inhibit 99% of the wild-type strains of
M. tuberculosis that were never in contact with this antibiotic, and is
the critical concentration used for the BACTEC
TM MGIT
TM 960
SIRE AST procedure [47,48]. Briefly, the exposure process for
strains susceptible to isoniazid began with the preparation of
MGIT tubes containing SIRE supplement (Becton Dickinson) and
0.1 mg/ml of isoniazid. These tubes were then inoculated with
0.5 ml of the initial culture and subsequently incubated at 37uCi n
the BACTEC 960 system until full growth was evident. For each
strain, this process was done in duplicate – see Figure 1 for
example.
For convenience, the various passages of the strains are identified
as follows: strain number, antibiotic, exposure process (A or B) and
the number of the passage. For example, H37RvINH (a)26 refers to
strain H37Rv exposed to isoniazid, exposure process A, passage 26
– see Figure 1 for example.
MIC determination and antibiotic susceptibility testing
(i) MIC determination. The MICs of the antibiotics and
efflux inhibitors (EIs) were performed in accordance to the
procedures issued by the manufacturer of the BACTEC 960
system revised by Springer et al. [48,49] for the parental strains at
the initial process and periodically for each of the progeny cultures
(Figure 1). The concentrations used were as follows: isoniazid:
0.025 to 256 mg/ml; verapamil: 30 to 512 mg/ml; thioridazine and
chlorpromazine: 7.5 to 60 mg/ml; EtBr: 0.25 to 4 mg/ml. At the
time of testing, two-fold serial dilutions were prepared to achieve
the desired concentrations. Each drug-containing tube was
inoculated with 0.8 ml of SIRE supplement, 0.1 ml of each drug
in the appropriated concentration and 0.5 ml of the culture. For
the preparation of the drug-free growth control tube (proportional
control), the culture was diluted 1:100 with a sterile saline solution
and 0.5 ml transferred into a new MGIT tube. Additionally, a
second drug-free growth control, inoculated with 0.5 ml of the
undiluted suspension of the strain, was prepared and served as
absolute control for inoculums errors. The tubes were inserted in
the BACTEC 960 system and growth monitored with the TB
eXIST module. The interpretation of the results was performed as
proposed by Springer et al. [49].
(ii) Isoniazid MIC determination in the presence of
EIs. The MICs of isoniazid (INH MIC) in combination with
the EIs were performed in the first passage where the increased
resistance was first noticed and in the last passage (#26) of the
serial exposure process to isoniazid – Figure 1. The EIs were used
at a concentration corresponding to K of the respective MIC.
This concentration was selected since it has no effect on the
growth of the strains following the protocol described above.
(iii) Susceptibility testing in the presence and absence of
EIs. For standard susceptibility testing against isoniazid,
rifampicin, pyrazinamide, streptomycin and ethambutol, the
readings were automatically interpreted by the BACTEC 960
system and reported as either susceptible or resistant. The
preparation of the drug containing tubes and controls was done
as described above. For the susceptibility testing for isoniazid in
the presence of the EIs, the tubes containing 0.1 mg/ml of
isoniazid were inoculated with the EI at K of the MIC.
Genotypic characterization of the strains
(i) DNA extraction. Genomic DNA was extracted using the
QIAamp DNA mini kit (QIAGEN, GmbH, Hilden, Germany)
according to the manufacturer’s instructions.
(ii) Screening of mutations. The most common mutations
in rpoB, katG and the mabA-inhA operon were screened during the
exposure process, using the system Genotype MTBDRplus (Hain
Lifescience GmbH, Nehren, Germany) according to the
manufacturer’s instructions.
(iii) DNA sequencing. The analysis of internal fragments of
the genes associated with isoniazid resistance, katG and the mabA-
inhA operon, was performed according to Perdiga ˜o et al. [50].
(iv) MIRU-VNTR analysis. MIRU-VNTR genotyping was
performed for each strain and at defined passages of the exposure
process by multiplex PCR amplification of 24 MIRU–VNTR loci,
as described by Supply et al. [51].
Quantification of expression of genes coding for efflux
pumps by RT-qPCR
(i) RNA extraction. Total RNA was isolated from the cells
using the RNeasy mini kit (QIAGEN) according to the
manufacturer’s instructions. Briefly, from a culture with 100–
200 GU (about 10
6–10
8 cells/ml), 1 ml aliquot was removed and
centrifuged at 13 000 rpm during 10 minutes. Then, 500 ml
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(QIAGEN) added. An enzymatic lysis step was carried out with
lysozyme at 3 mg/ml (Sigma) for 10 minutes, followed by lysis in
an ultrasonic bath at 35 kHz (Gen-Probe, California, USA) during
15 minutes. The RNA was then purified using the RNeasy kit
(QIAGEN) and treated with RNase-free DNase I (QIAGEN)
during 2 hours and 15 minutes by on-column digestion at room
temperature to reduce the presence of contaminating DNA. All
RNA samples were aliquoted and frozen at -20uC until required.
(ii) RT-qPCR assay. The relative expression level of the
genes that code for the main membrane efflux transporters in M.
tuberculosis (mmpL7, p55, efpA, mmr, Rv1258c and Rv2459) were
analyzed by RT-qPCR in the first passage where the increased
resistance was first noticed and in last passage (#26) of the
exposure process to isoniazid – Figure 1. The normalization of the
data was done using the M. tuberculosis 16S rDNA for each
experiment. The forward and reversed primers employed are
described in Table 6. The RT-qPCR procedure was performed in
a Rotor-Gene
TM 3000 thermocycler and followed the protocol
recommended for use with the QuantiTect SYBR Green RT-
PCR Kit (QIAGEN). The determination of the relative mRNA
expression level was performed using the comparative
quantification cycle (Cq) method [40]. The relative expression of
the six efflux pump genes analyzed was assessed by comparison of
the relative quantity of the respective mRNA in the presence of
isoniazid to the non-exposed culture, following the same technical
approach previously published [30]. Each culture was assayed in
triplicate using total RNA obtained from three independent
cultures. A level of relative expression equal to 1 indicates that the
expression level was identical to the unexposed strain. Genes
showing expression levels equal or above four, when compared
with the unexposed strain, were considered to be overexpressed
[39].
Semi-automated fluorometric method
This method allows the real-time fluorometric detection of the
accumulation and extrusion of EtBr, using the Rotor-Gene
3000
TM thermocycler (Corbett Research, Sidney, Australia)
[29,52]. The assays were performed based on the protocol
previously described [28,29,52] with modifications due to the
growth features of this microorganism, mainly the slow generation
time and the minimization of cell clumps. Increased biosafety
measures were taken to prevent the production and dispersal of
aerosols with infective particles since we were dealing with a Level
3 pathogen. The semi-automated fluorometric method was
applied to the initial strains and to the isoniazid exposed strains,
at the first passage where the increased resistance was first noticed
and in the last passage (#26) of the adaptation process to isoniazid
independently of the genetic background of each adapted culture.
The strains were grown in 100 ml of Middlebrook 7H9 medium
(DIFCO, Madrid, Spain) in Erlenmeyer flasks containing 10%
OADC enrichment (Becton Dickinson) and 0.05% Tween 80. All
cultures were incubated at 37uC, without stirring, until they
reached an approximate optical density at 600 nm (OD600) of 0.8
(mid-log phase). After the cultures reached the desired OD600,
25 ml cultures were centrifuged at 2700 g during 3 minutes at
25uC. After this, the supernatant were discarded, the pellet
washed, resuspended in PBS and centrifuged as before. This
procedure was performed twice. For accumulation assays, the
washed cells were re-suspended in PBS and the OD600 adjusted to
0.8. In order to determine the lowest concentration of EtBr that
causes accumulation, 50 ml of the bacterial suspension was added
to 0.2 ml PCR tubes containing different concentrations of EtBr
that ranged from 0.0625 to 5 mg/ml and glucose at a final
concentration of 0.4%. The final OD600 of the bacterial
suspension in the assay was 0.4. The assays were conducted at
37uC in a Rotor-Gene 3000
TM, and the fluorescence of EtBr was
measured (530/585 nm) at the end of each cycle of 60 seconds, for
60 minutes. After determining the higher concentration of EtBr
that do not causes accumulation, the effect of the EIs verapamil,
thioridazine and chlorpromazine on the accumulation of EtBr was
evaluated. These assays were performed like described above with
each EI at K of the MIC, EtBr at the higher concentration that do
not cause accumulation (determined for each strain and adapted
cultures), 37uC and with glucose.
Table 6. Sequences of the primers used in the RT-qPCR assays.
Gene Primer Sequence (59-39) Amplification product (bp) Reference
mmpL7_Fw TAC CCA AGC TGG AAA CAA 214 [36]
mmpL7_Rv CCG TCA GAA TAG AGG AAC CAG 214 [36]
p55_Fw AGT GGG AAA TAA GCC AGT AA 198 [36]
p55_Rv TGG TTG ATG TCG AGC TGT 198 [36]
efpA_Fw ATG GTA ATG CCT GAC ATC C 131 [36]
efpA_Rv CTA CGG GAA ACC AAC AAA G 131 [36]
mmr_Fw AAC CAG CCT GCT CAA AAG 221 [36]
mmr_Rv CAA CCA CCT TCA TCA CAG A 221 [36]
Rv1258c_Fw AGT TAT AGA TCG GCT GGA TG 268 [36]
Rv1258c_Rv GTG CTG TTC CCG AAA TAC 268 [36]
Rv2459_Fw CAT CTT CAT GGT GTT CGT G 232 This study
Rv2459_Rv CGG TAG CAC ACA GAC AAT AG 232 This study
16S_Fw CAA GGC TAA AAC TCA AAG GA 197 [36]
16S_Rv GGA CTT AAC CCA ACA TCT CA 197 [36]
FW: forward; RV: reverse.
doi:10.1371/journal.pone.0034538.t006
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